Non- SS | SS | ||
---|---|---|---|
(n = 98,310) | (n = 6554) | P-value | |
Age, years (mean ± SD) | 54 ± 14 | 54 ± 14 | 1 |
< 50 years | 34,140 (34.7) | 2276 (34.7) | |
≥ 50 years | 64,170 (65.3) | 4278 (65.3) | |
Gender | 1 | ||
Female | 86,760 (88.3) | 5784 (88.3) | |
Male | 11,550 (11.8) | 770 (11.8) | |
CCI (mean ± SD) | 0.4 ± 1.0 | 0.5 ± 0.9 | <0.001 |
CCI group | |||
0 | 76,836 (78.2) | 4541 (69.3) | |
≥ 1 | 21,474 (21.8) | 2013 (30.7) | |
Medications during all follow-up period | |||
Immunosuppressants | 837(0.9) | 1349(20.6) | <0.001 |
Methotrexate | 391(0.4) | 563(8.6) | <0.001 |
Azathioprine | 84(0.1) | 819(12.5) | <0.001 |
Cyclophosphamide | 425(0.4) | 208(3.2) | <0.001 |
Steroid | 38,348(39.0) | 4559(69.6) | <0.001 |
Medications during the first year | |||
Immunosuppressants | 413 (0.4) | 955 (14.6) | <0.001 |
Methotrexate | 214 (0.2) | 360 (5.5) | <0.001 |
Azathioprine | 41 (0.0) | 572 (8.7) | <0.001 |
Cyclophosphamide | 178 (0.2) | 150 (2.3) | <0.001 |
Steroid | 19,828 (20.2) | 3588 (54.8) | <0.001 |